Note: Ingredients listed on restricted chemical lists
General Information
Revision date
2018-01-26
Product name
Quetiapine extended-release tablets, USP
Product Synonyms
Quetiapine extended-release tablets, USP 150 mg, 200 mg, 300 mg and 400 mg
Chemical name
2-[2-(4-dibenzo [b,f] [1,4]thiazepin-11-yl-1-piperazinyl) ethoxy]- ethanol fumarate (2:1) (salt)
1.2.1 Relevant identified uses
Quetiapine extended-release tablets are indicated for the treatment of schizophrenia
Manufacturer Name
ScieGen Pharmaceuticals, Inc
Icons in SDS
Company Information
company name
ScieGen Pharmaceuticals, Inc
Section 2
SECTION 2: Hazards identification
Additional Hazard Accidental ingestion may cause effects similar to those seen in Information: Short Term: clinical use. Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on developing fetus and thyroid Adverse effects associated with therapeutic use include dizziness, sleepiness (somnolence) dry mouth, constipation, difficult Known Clinical Effects: digestion (dyspepsia), low blood pressure on standing (orthostatic hypotension), increased heart rate (tachycardia). May cause harm to breastfed babies. Causes eye irritation. May damage the unborn child.
Hazard statements
May cause harm to breastfed babies. Toxic to aquatic life with long lasting effects
EU Classification
Toxic to Reproduction: Category 2 EU Indication of danger Dangerous for the Environment Australian Hazard R51/53 - Toxic to aquatic organisms, may c ause long-term
Hazard classification according to the criteria of NOHSC
adverse effects in the aquatic environment.
Hazardous Ingredients
Non-Dangerous Goods
